Moderna (MRNA) Revenue — Quarter Ended Mar 31, 2023
Revenue declined sharply in the current quarter. The decrease was steeper compared to both the prior quarter and the same quarter a year earlier.
Key takeaway
Quarter ended Mar 31, 2023 · FY2023 Q1
Revenue declined sharply in the current quarter. The decrease was steeper compared to both the prior quarter and the same quarter a year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.9B
Revenue reported for this quarter.
Quarter-over-quarter
-63.4%
Change from the immediately preceding quarter.
Year-over-year
-69.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$15.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2022 | $4.7B | +9.1% |
| Sep 30, 2022 | $3.4B | -32.3% |
| Dec 31, 2022 | $5.1B | -29.5% |
| Mar 31, 2023 | $1.9B | -69.3% |
Revenue performance
Reported revenue fell significantly from the immediately preceding quarter. The year-over-year comparison also showed a substantial decline.
Quarterly comparison
Revenue was lower than both the prior quarter and the same quarter one year ago. The sequential and annual declines were both material.
What to watch
Monitor whether the downward revenue trend continues in subsequent quarters.